Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood Samples, L., Sadrzadeh, H., Frigault, M. J., Jacobson, C. A., Hamadani, M., Gurumurthi, A., Strati, P., Shouval, R., Noy, A., Riedell, P. A., Dahiya, S., Maloney, D. G., Till, B. G., Hirayama, A. V., Gauthier, J., Gopal, A. K., Smith, S. D., Poh, C., Lynch, R. C., Ujjani, C., Di, M., Raghunathan, V., Shakib-Azar, M., Naresh, K. N., Gooley, T. A., Yared, J. A., Jain, M. D., Locke, F. L., Leslie, L. A., Epperla, N., Ghosh, M., Skarbnik, A. P., Hill, B. T., Kamdar, M., Ortiz-Maldonado, V., Martínez-Cibrian, N., Shune, L., Shadman, M. 2025

Abstract

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T-cells after a median of 3 prior therapies (range 1-6). Patients received axi-cel (n = 19), liso-cel (n = 4), tisa-cel (n = 4) or other agents (n = 4). Grade 1-2 CRS occurred in 83.9% of patients (grade =3 6.5%), and grade 1-2 ICANS occurred in 29% of patients (grade =3 19.4%). Twenty-eight-day mortality was 16.1%, including one patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%, however the 6-month CR rate was only 25.8%. Median progression-free survival was 2.3 months (95% CI 1.0 - 9.0), and median overall survival was 6.0 months (95% CI 1.9 - 11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long term disease control in BL. Further investigation is needed to determine the most effective alternative management of these patients.

View details for DOI 10.1182/blood.2024026831

View details for PubMedID 39938007